FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology, specifically to cellular technologies, and can be used to induce tolerance or suppress the immune response to an antigen in an individual. The method of inducing tolerance or suppressing the immune response to an antigen involves passing a cell suspension containing an immune cell through a constriction, and the constriction deforms the cell, thereby causing a disturbance in the cell, so that the antigen and/or the tolerogenic factor penetrates the cell, thereby forming a tolerant and/or immunosuppressive immune cell.
EFFECT: invention provides effective delivery of a payload-an antigen or a tolerogenic factor to immune cells, which can be used to induce immunity of the body to the specified agent.
200 cl, 12 dwg, 9 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
INTRACELLULAR DELIVERY OF BIOLOGICAL MOLECULES FOR TOLERANCE INDUCING | 2017 |
|
RU2770492C2 |
DELIVERY OF BIOMOLECULES INTO CELLS OF IMMUNE SYSTEM | 2015 |
|
RU2739794C2 |
PEPTIDE CONJUGATED PARTICLES | 2013 |
|
RU2669346C2 |
RNA FOR TREATMENT OF AUTOIMMUNE DISEASES | 2018 |
|
RU2790447C2 |
PEPTIDE | 2014 |
|
RU2675479C2 |
MUCOSAL INDUCTION OF ANTIGEN TOLERANCE | 2006 |
|
RU2420569C2 |
PEPTIDE CONJUGATED PARTICLES | 2014 |
|
RU2685186C2 |
PEPTIDE | 2014 |
|
RU2667428C2 |
METHODS RELATED TO ACTIVATED DENDRITIC CELLS COMPOSITIONS AND TO IMMUNOTHERAPEUTIC TREATMENT OF INDIVIDUALS WITH ADVANCED CANCER | 2016 |
|
RU2749610C2 |
PHARMACEUTICAL COMPOSITION POSSESSING ANTITUMOUR EFFECT, AND METHOD FOR REDUCING PD-L1 INHIBITING EFFECT ON HUMAN T-CELLS | 2016 |
|
RU2688692C2 |
Authors
Dates
2021-05-17—Published
2017-05-03—Filed